Fresenius SE (0OO9) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Fresenius SE €86.98, price €43.68, upside +99.1%, quality 50 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
How to read this chart
60‑month range €18.40 – €50.79 · fair‑value band €49.33 – €123.41 · the €43.68 price screens below the €86.98 fair value. Dashed = 300-day average. As of Sep 29, 2026.
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments.
Show more
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.
Stock analysis
Fresenius SE (0OO9) currently trades at €43.68, while our model-based Fair Value estimate is €86.98, implying the stock looks roughly 49.8% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of €91.52 per share, and 19 of the 24 models we run sit above the €43.68 price.
Bear case: the Asset-Based group reads lowest at €23.86, and 5 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: €49.33 (bear) to €123.41 (bull), the price of €43.68 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Fresenius SE reported revenue of €36.3B in FY2020 versus €29.5B in FY2016, a compound +5.3%/yr. Reported net income was €1.7B in FY2020, compounding +2.3%/yr from FY2016.
Key figures
Market cap €20.8B · P/S ratio 0.90 · Dividend yield 2.4% · Net margin 4.7% · Return on equity 7.8% · Return on assets (EBIT) 8.1% · Operating margin 10.2% · Revenue (TTM) €23.0B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 14% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 21% fair-value upside, at 99%, 0OO9 screens cheaper than that median.
Fair Value models
Bear €49.33Fair Value €86.98Bull €123.41
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.54/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+2.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.6% (2016) → 12.1% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Fresenius SE Fair Value". https://www.fairvalue-calculator.com/stock/0OO9
Frequently asked questions
Is Fresenius SE (0OO9) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of €86.98 versus a price of €43.68, about +99% upside (undervalued).
What is the fair value of 0OO9?
Our model-based fair value for Fresenius SE is €86.98 (as of Sep 29, 2026), built from audited fundamentals. The current price: €43.68.
What is the quality score of 0OO9?
Fresenius SE has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fresenius SE (0OO9)?
Our model-based price target is the fair value of €86.98 (as of Sep 29, 2026) from 24 valuation models. Cautious scenario €49.33, optimistic scenario €123.41. It is a calculation from audited fundamentals, not an analyst target.
What is the Fresenius SE stock forecast for 2026?
Our models put fair value at €86.98, about +99% upside versus a price of €43.68 (undervalued). Cautious scenario €49.33, optimistic scenario €123.41. The calculation is refreshed regularly with new filings.
What is the revenue of Fresenius SE (0OO9)?
Fresenius SE reported trailing-twelve-month revenue of about €23.0B (latest available figure, as of Sep 29, 2026).
Does Fresenius SE pay a dividend?
Fresenius SE currently shows a dividend yield of about 2.40% relative to its recent price (as of Sep 29, 2026).
What is the intrinsic value of Fresenius SE (0OO9)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fresenius SE it is €86.98 per share (as of Sep 29, 2026), against a price of €43.68. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Fresenius SE stock overvalued or undervalued in 2026?
As of Sep 29, 2026, 0OO9 trades below its calculated fair value: price €43.68, fair value €86.98, a gap of about +99% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0OO9?
No. The price is what the market pays today (€43.68); the fair value is what the company's own numbers justify (€86.98). For Fresenius SE the two are €43.30 per share apart. That gap is exactly why we show both numbers side by side.
How much is Fresenius SE worth?
The market values Fresenius SE at about €20.8B (market capitalisation, as of Sep 29, 2026). Per share that is €43.68; our models calculate a fair value of €86.98 per share.
What do the bullish and bearish scenarios say about 0OO9?
Our models span a range for Fresenius SE: cautious scenario €49.33, base €86.98, optimistic €123.41 per share (as of Sep 29, 2026, price €43.68). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0OO9 from its 52-week high?
Fresenius SE trades at €43.68, about 14% below its 52-week high of €50.79 and 23% above the low of €35.45 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €86.98 is for.
Which stocks are comparable to Fresenius SE?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fresenius SE stock attractive at the current price?
The data as of Sep 29, 2026: price €43.68, calculated fair value €86.98 (+99%), Quality Score 50/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0OO9 calculated?
We run Fresenius SE through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €86.98, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Fresenius SE currently trades 50 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Fresenius SE (0OO9)?
The closing price on Oct 2, 2026 was €43.68. Our model-based fair value is €86.98, about +99% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Fresenius SE right now?
The price is below even our cautious bear case (€49.33). The market is more pessimistic than our downside scenario. Solid quality (50/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (€49.33 to €123.41) leaves room in how you read the outcome.
Key figures of Fresenius SE
How large is the market capitalisation of Fresenius SE (0OO9)?
The market capitalisation of Fresenius SE is €20.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Fresenius SE (0OO9)?
The price-to-sales ratio of Fresenius SE is 0.90 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Fresenius SE (0OO9)?
The dividend yield of Fresenius SE is 2.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Fresenius SE (0OO9)?
The net margin of Fresenius SE is 4.7% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Fresenius SE (0OO9)?
The return on equity (ROE) of Fresenius SE is 7.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Fresenius SE (0OO9)?
On an EBIT basis the return on assets of Fresenius SE is 8.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Fresenius SE (0OO9)?
The operating margin of Fresenius SE is 10.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Fresenius SE (0OO9)?
Revenue at Fresenius SE is growing +2.0% versus a year earlier (3y avg +2.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Fresenius SE (0OO9)?
Earnings per share at Fresenius SE are growing +90.0% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
